SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023)

SAB Biotherapeutics' Construction in Progress history runs 3 years deep, the most recent figure standing at $329617.0 for Q1 2023.

• Quarterly Construction in Progress changed N/A year-over-year to $329617.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $329617.0 (changed N/A YoY) and the FY2022 annual result came in at $137811.0, down 35.47% from the prior year.
• Construction in Progress was $329617.0 for Q1 2023 at SAB Biotherapeutics, up from $137811.0 in the prior quarter.
• Across five years, Construction in Progress topped out at $329617.0 in Q1 2023 and bottomed at $137811.0 in Q4 2022.
• A 3-year average of $226997.3 and a median of $213564.0 in 2021 frame the typical range for Construction in Progress.
• Peak annual rise in Construction in Progress reached 35.47% in 2022, while the deepest fall reached 35.47% in 2022.
• SAB Biotherapeutics' Construction in Progress stood at $213564.0 in 2021, then slumped by 35.47% to $137811.0 in 2022, then jumped by 139.18% to $329617.0 in 2023.
• Business Quant data shows SABS's Construction in Progress at $329617.0 in Q1 2023, $137811.0 in Q4 2022, and $213564.0 in Q4 2021.